Andrea Lobo,  —

SandboxAQ has signed a $25 million research grant through an initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new treatments that target the LRRK2 gene, mutations in which are one of the most common genetic causes of Parkinson’s disease. Under the partnership, which…

Besides motor challenges, people with Parkinson’s disease have difficulty with motor imagery, or generating a mental representation of a movement, a study showed. That’s particularly true for the more affected side of the body. “Even when people with Parkinson’s think about movement, it’s different for their more affected side,”…

A new partnership will work to develop customized assays to detect and quantify blood biomarkers to support the advancement of new treatments for neurodegenerative diseases, including Parkinson’s disease. Adx Neurosciences, which makes biomarker assays for neurodegenerative diseases, and Alamar Biosciences, a proteomics company with technology to detect…

Hearing loss may be a risk factor for later developing Parkinson’s disease, and the risk may be higher for people with more severe impairment, according to a recent study of U.S. military veterans data. However, the use of hearing aids within two years after the diagnosis of hearing difficulties…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced an initiative to accelerate the identification of biomarkers and the development of new therapies targeting the LRRK2 gene, one of the most common causes of inherited Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange, or LITE, provides “tens…

The American Parkinson Disease Association (APDA) is funding a new APDA Center for Advanced Research at Yale University’s School of Medicine, the newest of nine such centers in its U.S. network, in recognition of the school’s work into the causes and the potential for personalized treatment of Parkinson’s…

Booster Therapeutics announced its launch and the start of work into therapeutics that improve the body’s ability to clear itself of the defective, disease-causing proteins that drive Parkinson’s disease and other neurodegenerative conditions. The company, which is based in Berlin and whose opening was supported by $15 million…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…

Gain Therapeutics has presented new preclinical data showing GT-02287, its experimental therapy for Parkinson’s disease, can slow disease progression in mouse and cellular models of the disease. Overall, the treatment was shown to improve motor function and coordination, and activities of daily living in mouse models of Parkinson’s…

Researchers at New York University (NYU) Langone Health were awarded a two-year, $1.6 million grant by the National Institutes of Health (NIH) to investigate eye changes as potential early signs and progression markers of Parkinson’s disease and Alzheimer’s. The grant, given under the NIH Common Fund Venture Program’s…